Axl and autophagy LC3 expression in tumors is strongly associated with clinical prognosis of hepatocellular carcinoma patients after curative resection

High Axl expression in tumors is associated with aggressive tumor behavior and worse clinical outcomes.The combination of high Axl and low LC3 expression significantly predicts poorer prognosis in HCC patients who underwent hepatectomy. AbstractBackgroundThe role of Axl and LC3 as predictors of tumor recurrence and overall survival (OS) after hepatocellular carcinoma (HCC) resection remains unclear.MethodsWe retrospectively included 535 HCC patients who underwent hepatectomy from 2010 to 2014 in this study. Axl and the autophagy ‐related marker LC3 were immunohistochemically assessed in tumors.ResultsAxl expression was significantly associated with advanced clinicopathological features, including cirrhosis, microvascular invasion, macrovascular invasion, tumor size, BCLC stage, recurrence, and mortality. HCC recurrence occurred in 245 patients, and 219 patients died. The 5 ‐year cumulative incidences of HCC recurrence and OS rate after HCC resection were 53.3% and 58.8%, respectively. In the Cox proportional analyses, high Axl expression and high LC3 expression were significantly associated with HCC recurrence (hazard ratio [HR]: 3.85, 95% confidence interval [CI]: 2.95‐5.02,P 
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research

Related Links:

ConclusionRepeat hepatectomy has favorable long-term outcomes. Cirrhosis and HBV not treated with antiviral therapy were associated with immediate postoperative morbidity. Serum AFP> 20 ng/mL at first resection, PH, and GVI at recurrence are independent prognostic factors. For patients without PH, TNM staging can predict prognosis.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
This study aimed to evaluate the prognostic value of achieving low liver stiffness measurement (LSM) in patients with cirrhosis confirmed from the resected liver due to hepatocellular carcinoma (HCC). A total of 184 patients that received curative surgery for HCC related to the hepatitis B virus at Barcelona Clinic Liver Cancer stage 0–A, and had a METAVIR fibrosis score of 4 were investigated. LSM significantly decreased after antiviral therapy during follow-up (p = 0.001), and achieving LSM ≤8 kilopascal (kPa) suggested a reduced risk of late recurrence (>12 months) (hazard ratio (HR), 0.519; 95% ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionsTo our knowledge, this is the first study exploring HBV-related NHL in non-endemic areas. Interestingly, more than 40% of patients were born in high-endemic areas. The strong predominance of DLBCL (59%) is concordant with studies performed in high-incidence areas. Strikingly, it contrasts with the peculiar distribution of HCV-related NHL supporting that some different pathophysiological mechanisms contribute to NHL in HBV. However, as in HCV-related NHL, frequent hepatic or digestive involvement raises the hypothesis of home privileged lymphomagenesis favored by viral induced inflammation or by infection of B-ce...
Source: Blood - Category: Hematology Authors: Tags: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies: Poster III Source Type: research
This study assessed the prognostic role of LSPS score (liver stiffness value X spleen diameter/platelet count) in predicting these goals in cirrhotic patients responsive to antiviral therapy. METHODS: The correlation between LSPS, PH, esophageal varices (EVs) and HCC was evaluated in 121 cirrhotic patients treated with nucleos(t)ide analogues (NUCs). Sixty-one patients (50.4%) had PH at baseline. All were HBV DNA negative on-treatment. They were evaluated after a median of 8 years of therapy (1-17) for LSPS, PH, hepatic venous pressure gradient (HVPG), EVs and HCC. RESULTS: LSPS ≤0.62 and ≤ 1.4 identified pat...
Source: Minerva Gastroenterologica e Dietologica - Category: Gastroenterology Tags: Minerva Gastroenterol Dietol Source Type: research
Optimal care for hepatitis virus –related hepatocellular carcinoma (HCC) would include eradication of tumor and elimination of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Accomplishing these goals could prevent deaths from cancer or cirrhosis and reduce the likelihood of viral transmission. Tremendous progress h as recently been achieved for tumor and antiviral therapies. Long-term survival from cancer was previously a rarity. Now, partial hepatectomy, liver transplant, or tumor ablation provide 5-year survival rates of 45% to 80%. Direct-acting antivirals (DAA) can now prevent cirrhosis in patients...
Source: JAMA Surgery - Category: Sports Medicine Source Type: research
Cancers, Vol. 10, Pages 183: Clinico-Pathological Importance of TGF-β/Phospho-Smad Signaling during Human Hepatic Fibrocarcinogenesis Cancers doi: 10.3390/cancers10060183 Authors: Katsunori Yoshida Koichi Matsuzaki Miki Murata Takashi Yamaguchi Kanehiko Suwa Kazuichi Okazaki Chronic viral hepatitis is a global public health problem, with approximately 570 million persons chronically infected. Hepatitis B and C viruses increase the risk of morbidity and mortality from liver cirrhosis, hepatocellular carcinoma (HCC), and extrahepatic complications that develop. Hepatitis virus infection induces transfo...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Abstract Hepatocellular carcinoma (HCC) is the most common form of liver cancer and has a poor prognosis and a low survival rate; its incidence is on the rise. Hepatitis B virus (HBV) infection is one of the main causes of HCC. A high prevalence of pre‐S deletions of HBV surface antigen, which encompass T‐cell and/or B‐cell epitopes, is found in HBV carriers; antiviral therapy and viral immune escape may cause and select for these HBV mutants. In particular, the presence of pre‐S2 deletion mutants is an important risk factor associated with cirrhosis and HCC. We generated Alb‐pre∆S2 transgenic mice that express...
Source: The Journal of Pathology - Category: Pathology Authors: Tags: Original Paper Source Type: research
Conclusions The incidence of HCC among chronic HBV carriers in West Africa was higher than that in Europe but lower than rates in East Asia. High risk of severe liver disease among the few who are infected by their mothers underlines the importance of interrupting perinatal transmission in sub-Saharan Africa.
Source: Gut - Category: Gastroenterology Authors: Tags: Cirrhosis, Hepatic cancer Hepatology Source Type: research
AbstractChronic hepatitis B infection represents a global public health burden, infecting over 240 million persons worldwide. It is associated with significant morbidity and mortality and represents a leading cause for cirrhosis, liver failure, liver cancer, and liver-related death. Current treatment of hepatitis B is focused on identification of patients with active hepatitis within the immune clearance or reactivation phases of chronic infection, for whom antiviral therapy with peg-interferon or nucleos(t)ide analogs are recommended. Seven antiviral agents are currently approved by the US FDA for treatment of chronic hep...
Source: Current Hepatitis Reports - Category: Infectious Diseases Source Type: research
Rohit Goyal, Subrat K AcharyaHepatitis B Annual 2011 8(1):32-70Hepatitis B virus (HBV) is the most important cause of chronic liver disease and hepatocellular carcinoma in India. During the past three decades, considerable advances in the diagnosis and treatment of HBV infection have been achieved. However, despite the remarkable improvements, medical management for HBV induced cirrhosis, and liver cancer remains unsatisfactory. In fact, it is becoming increasingly clear that as of now, there is no "cure" for hepatitis B infection. Management of chronic hepatitis B has changed considerably; currently, emphasis is...
Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1) - Category: Hematology Authors: Source Type: research
More News: Antiviral Therapy | Cancer | Cancer & Oncology | Carcinoma | Chia | Cirrhosis | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Liver Cancer | Study